Skip to main
  1. Stocks
  2. Viridian Therapeutics
  3. Forecast
VRDN

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics is attractive because its lead TED franchise has already shown differentiated clinical performance, with veligrotug meeting pivotal endpoints and the launch of Lumvoa generating $24.7M in first-quarter net product revenue and more than 100 patients on therapy. The company also has a strong balance sheet, with $955.2M in cash, cash equivalents, and marketable securities, which supports operations through profitability while management invests in commercialization and pipeline expansion. Beyond TED, the -74% IgG reduction and favorable safety profile for VRDN-008, plus a planned pivotal study in mid-2027 and modeled FY31 revenue of $269M in its first four quarters, add meaningful diversification and longer-term upside.

Bears say

Viridian Therapeutics is exposed to substantial regulatory risk because accelerated approval strategies may still require additional data, longer studies, or revised requirements, and any label that lacks key features could weaken commercial adoption. Its outlook is also pressured by execution and competition, since underperformance could hurt shares while AMGN, IMVT, and private or generic rivals can shift sentiment in either direction. The company likely needs additional external funding to advance its development platform, and inability to access capital markets could delay or halt programs; if veligrotug fails on efficacy or safety in TED, the stock could trade near net cash with minimal pipeline value at $14/sh.

Viridian Therapeutics (VRDN) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction

Get the latest Viridian Therapeutics (VRDN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Viridian Therapeutics (VRDN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 11 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction

Get the latest Viridian Therapeutics (VRDN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Viridian Therapeutics (VRDN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover VRDN stock data and trends